<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Original Research Protection of Cattle Elicited Using a Bivalent Lumpy" exact="Skin Disease" post="Virus-Vectored Recombinant Rift Valley Fever Vaccine WallaceDavid B.12*MatherA.1KaraP. D.1NaickerLeeann3MokoenaNobalanda"/>
 <result pre="Research Protection of Cattle Elicited Using a Bivalent Lumpy Skin" exact="Disease" post="Virus-Vectored Recombinant Rift Valley Fever Vaccine WallaceDavid B.12*MatherA.1KaraP. D.1NaickerLeeann3MokoenaNobalanda"/>
 <result pre="Using a Bivalent Lumpy Skin Disease Virus-Vectored Recombinant Rift Valley" exact="Fever" post="Vaccine WallaceDavid B.12*MatherA.1KaraP. D.1NaickerLeeann3MokoenaNobalanda B.3PretoriusA.1NefefeT.1ThemaN.1BabiukShawn45[], 1Vaccines and Diagnostics Development"/>
 <result pre="David B. Wallace WallaceD@arc.agric.za This article was submitted to Veterinary" exact="Infectious" post="Diseases, a section of the journal Frontiers in Veterinary"/>
 <result pre="permitted which does not comply with these terms. Abstract Lumpy" exact="skin disease" post="and Rift Valley fever are two high-priority livestock diseases"/>
 <result pre="which does not comply with these terms. Abstract Lumpy skin" exact="disease" post="and Rift Valley fever are two high-priority livestock diseases"/>
 <result pre="not comply with these terms. Abstract Lumpy skin disease and" exact="Rift Valley fever" post="are two high-priority livestock diseases which have the potential"/>
 <result pre="to the more consistent and sustainable use of vaccination against" exact="Rift Valley fever" post="through a more cost-effective vaccine. In this study, a"/>
 <result pre="a more cost-effective vaccine. In this study, a recombinant lumpy" exact="skin disease" post="virus was constructed in which the thymidine kinase gene"/>
 <result pre="more cost-effective vaccine. In this study, a recombinant lumpy skin" exact="disease" post="virus was constructed in which the thymidine kinase gene"/>
 <result pre="site for the Gn and Gc protective glycoprotein genes of" exact="Rift Valley fever" post="virus using homologous recombination. Selection markers, the enhanced green"/>
 <result pre="cattle as a vaccine to show protection against both lumpy" exact="skin disease" post="and Rift Valley fever in cattle. The results demonstrate"/>
 <result pre="as a vaccine to show protection against both lumpy skin" exact="disease" post="and Rift Valley fever in cattle. The results demonstrate"/>
 <result pre="vaccine to show protection against both lumpy skin disease and" exact="Rift Valley fever" post="in cattle. The results demonstrate that the LSD-RVF.mf is"/>
 <result pre="safe, immunogenic and can protect cattle against both diseases. lumpy" exact="skin disease" post="recombination vaccine Rift Valley fever cattle Funding International Development"/>
 <result pre="immunogenic and can protect cattle against both diseases. lumpy skin" exact="disease" post="recombination vaccine Rift Valley fever cattle Funding International Development"/>
 <result pre="protect cattle against both diseases. lumpy skin disease recombination vaccine" exact="Rift Valley fever" post="cattle Funding International Development Research Centre10.13039/501100000193 fig-count: table-count: equation-count:"/>
 <result pre="in the family Poxviridae comprised of sheeppox, goatpox and lumpy" exact="skin disease" post="viruses. Lumpy skin disease (LSD) causes fever and skin"/>
 <result pre="the family Poxviridae comprised of sheeppox, goatpox and lumpy skin" exact="disease" post="viruses. Lumpy skin disease (LSD) causes fever and skin"/>
 <result pre="comprised of sheeppox, goatpox and lumpy skin disease viruses. Lumpy" exact="skin disease" post="(LSD) causes fever and skin lesions in cattle leading"/>
 <result pre="of sheeppox, goatpox and lumpy skin disease viruses. Lumpy skin" exact="disease" post="(LSD) causes fever and skin lesions in cattle leading"/>
 <result pre="(1). No country in sub-Saharan Africa claimed freedom from this" exact="disease" post="since its discovery (OIE, HandiSTATUS, 02/02/05). LSD has rapidly"/>
 <result pre="(3), currently as far as China, Bangladesh and India. The" exact="disease" post="is most likely spread by insect and other arthropod"/>
 <result pre="via mechanical transmission and is not highly contagious in the" exact="absence of" post="potential vectors. This makes control of LSD difficult and"/>
 <result pre="more recently demonstrated in Europe using mass vaccination (4). Lumpy" exact="skin disease" post="and sheep and goat pox are ranked in the"/>
 <result pre="recently demonstrated in Europe using mass vaccination (4). Lumpy skin" exact="disease" post="and sheep and goat pox are ranked in the"/>
 <result pre="top 20 global diseases for impact on the poor (5)." exact="Rift Valley fever" post="virus (RVFV) is an RNA virus and member of"/>
 <result pre="Kenya in the Rift Valley (7). The geographic distribution of" exact="Rift Valley fever" post="(RVF) was limited to sub-Saharan Africa until outbreaks in"/>
 <result pre="(7). The geographic distribution of Rift Valley fever (RVF) was" exact="limited" post="to sub-Saharan Africa until outbreaks in Egypt in the"/>
 <result pre="always the risk of new outbreaks, which could become endemic." exact="Rift Valley fever" post="virus is a vector-borne pathogen spread by mosquitos and"/>
 <result pre="of ruminants including cattle, sheep, goats and camels. In livestock," exact="disease" post="is characterized by fever, diarrhea, and abortions. Unlike LSDV,"/>
 <result pre="Onderstepoort Biological Products (OBP Ltd). This vaccine utilizes the South" exact="African" post="live attenuated Onderstepoort LSD vaccine as vector, which co-expresses"/>
 <result pre="the RVFV structural glycoprotein (GP) genes under control of the" exact="vaccinia" post="virus P7.5K early/late promoter inserted into the LSDV viral"/>
 <result pre="the vaccinia virus P7.5K early/late promoter inserted into the LSDV" exact="viral" post="thymidine kinase gene (14). Two selectable marker genes are"/>
 <result pre="This is routinely achieved for other poxvirus-vectored vaccine constructs using" exact="transient" post="dominant selection (17, 18). As described in this paper,"/>
 <result pre="the bivalent LSD-RVF.mf vaccine includes: (1) preventing mortality and debilitating" exact="disease" post="in cattle caused by LSD and RVF in all"/>
 <result pre="(2) indirectly protecting people from RVF virus by decreasing the" exact="viral" post="loads in livestock; and (3) helping provide an effective"/>
 <result pre="are presented here. Materials and Methods Cells and Viruses Cells" exact="Primary" post="fetal bovine testes (FBT) cells were prepared according to"/>
 <result pre="Materials and Methods Cells and Viruses Cells Primary fetal bovine" exact="testes" post="(FBT) cells were prepared according to standard techniques (20)."/>
 <result pre="performed using Madin-Darby bovine kidney (MDBK) cells (obtained from the" exact="American" post="Type Tissue Culture Collection, no. CCL-22, USA) and baby"/>
 <result pre="USA) and baby hamster kidney (BHK) cells (obtained from the" exact="American" post="Type Tissue Culture Collection, no. CCL-10, USA) for preparation"/>
 <result pre="of the RVFV challenge strain, as below. Viruses The South" exact="African" post="Neethling vaccine strain of LSDV, produced by Onderstepoort Biological"/>
 <result pre="containing the virus was reconstituted in 1 ml Eagle's Minimum" exact="Essential" post="Medium (EMEM) (Gibco, USA) and seeded onto a 90%"/>
 <result pre="vector, pLS(EG), was developed with insertion of the positive and" exact="visual" post="selection marker genes, the E. coli gpt and EGFP"/>
 <result pre="the addition of a second round of selection in the" exact="absence of" post="mycophenolic acid (MPA) selection pressure, resulting in a product"/>
 <result pre="in a product free from both marker genes [known as" exact="transient" post="dominant selection (17, 18)]. However, as a potential by-product"/>
 <result pre="cells incubated for 1 h at 37°C with 100 μl/well" exact="Protein" post="G-conjugated horseradish immunoperoxidase (Invitrogen, USA) diluted 1:10 000 in"/>
 <result pre="Released virus was propagated and once cells displayed 100% cpe," exact="viral" post="and cellular DNA was purified using the Roche Magna"/>
 <result pre="and cellular DNA was purified using the Roche Magna Pure" exact="Total" post="nucleic acid extraction kit (Roche, Switzerland) and a Roche"/>
 <result pre="MagNA Pure LC 2.0 extractor according to the manufacturer's instructions." exact="Viral" post="foci were then characterized for homogeneity (free from parental"/>
 <result pre="Animal Ethics Committee (approval no. AEC 4.17) and the South" exact="African" post="Department of Agriculture, Forestry and Fisheries (DAFF) (Section 20"/>
 <result pre="Agriculture, Forestry and Fisheries (DAFF) (Section 20 of the South" exact="African" post="Animal Diseases Act [Act No 35 of 1984] permit"/>
 <result pre="and Fisheries (DAFF) (Section 20 of the South African Animal" exact="Diseases" post="Act [Act No 35 of 1984] permit no. 12/11/1/1/15)."/>
 <result pre="were then selected, purchased and delivered to the ARC–Transboundary Animal" exact="Diseases" post="(TADs) biosafety containment level-3 facilities, of which twenty were"/>
 <result pre="equal volume of Lysis/binding buffer from the MagNA Pure LC" exact="total" post="nucleic acid isolation kit (Roche, Switzerland) was added to"/>
 <result pre="at −20°C until further use. Once the samples were thawed," exact="total" post="nucleic acid extraction was performed using the kit (following"/>
 <result pre="detection of LSDV antigen and gross cellular pathology related to" exact="virus infection" post="(Idexx Laboratories, South Africa). Humoral Immunity Sera was recovered"/>
 <result pre="of LSDV antigen and gross cellular pathology related to virus" exact="infection" post="(Idexx Laboratories, South Africa). Humoral Immunity Sera was recovered"/>
 <result pre="mouse anti-bovine CD8α-FITC (Clone 38.65, IgG1, BioRad), mouse anti-bovine CD4" exact="primary" post="antibody (cell line GC50A1, IgM, VMRD Inc, USA) and"/>
 <result pre="line GC50A1, IgM, VMRD Inc, USA) and goat anti-mouse IgM-APC" exact="secondary" post="antibody (1:8 dilution; Invitrogen, UK). Flow cytometry data acquisition"/>
 <result pre="of challenge and 3, 6, 9, 14, and 21 dpc." exact="Total" post="nucleic acid was extracted from serum samples using the"/>
 <result pre="acid was extracted from serum samples using the MagNA Pure" exact="Total" post="Nucleic Acid Kit (High Performance) (Roche, Switzerland). The real-time"/>
 <result pre="picking, followed by the progeny virions being grown in the" exact="absence of" post="MPA to allow for removal of the selection markers."/>
 <result pre="of the EGFP and gpt selection marker genes - LSD-RVF.mf." exact="Multiple" post="foci lacking EGFP expression were selected, half portions of"/>
 <result pre="correct size (~ 5.5 kpb) for the recombinant virus and" exact="absence of" post="any amplification products of 1.9 kbp, indicative of parental"/>
 <result pre="of pyrexia (&amp;gt;39.5°C) were observed for any of the calves." exact="Protection Against" post="LSDV Challenge LSD Clinical Evaluation Following virus challenge with"/>
 <result pre="using detection of LSDV DNA in blood using conventional PCR." exact="Viral" post="nucleic acid was not detected in the control or"/>
 <result pre="via conventional PCR at any time points tested, post-challenge. LSDV-Specific" exact="Antibody" post="Responses Following Vaccination and Challenge Sera were evaluated at"/>
 <result pre="A1-1 to A1-5) when stimulated with LSDV antigen (Figure 5A)." exact="Increased" post="numbers of IFN-γ -producing cells were detected in Group"/>
 <result pre="(B) Group 2 (vaccinated and RVFV challenged) animals stimulated with" exact="Rift Valley fever" post="virus (RVFV) antigen. Averages for the Group 1 (mock-vaccinated"/>
 <result pre="negative control group with P ≤ 0.01, are indicated with**." exact="Protection Against" post="RVF Challenge RVF Clinical Evaluation Animals in the control"/>
 <result pre="Control animal D2-2's temperature peaked at 42.2°C and it developed" exact="diarrhea" post="6 dpc. One control animal (D2-5) died at 5"/>
 <result pre="of necrosis surrounded by hemorrhagic hepatic parenchyma. Petechiae of the" exact="mucosa" post="of the gall bladder and diffuse hemorrhaging of lymph"/>
 <result pre="parenchyma. Petechiae of the mucosa of the gall bladder and" exact="diffuse" post="hemorrhaging of lymph nodes were observed – thus, the"/>
 <result pre="observed – thus, the cause of death was linked to" exact="acute" post="RVFV infection. Liver, kidney and spleen samples were sent"/>
 <result pre="for histopathology and IHC staining and evaluation related to RVFV" exact="infection" post="(Idexx Laboratories, South Africa). Positive staining for RVFV antigen"/>
 <result pre="typical of RVFV infection. No gross pathology consistent with RVFV" exact="infection" post="was observed in organs of the remainder of the"/>
 <result pre="assessed by detecting RVFV genomic sequences in sera using qRT-PCR." exact="Viral" post="genomes were detected in the mock-vaccinated calves 3 dpc"/>
 <result pre="lowest Ct value at 3 dpc, and succumbed to RVFV" exact="infection" post="by 5 dpc. In contrast, RVFV was detected in"/>
 <result pre="animals and (B) vaccinated animals after challenge with RVFV. RVFV-Specific" exact="Antibody" post="Responses Following Vaccination and Challenge The mock-vaccinated animals had"/>
 <result pre="than in the mock-vaccinated group by 6 dpc (Figure 9A)." exact="Rift Valley fever" post="virus neutralizing antibodies were present in three of the"/>
 <result pre="at 3 day's post-challenge (dpc), however, the animal died of" exact="acute" post="RVF at 5 dpc. (B) Three calves inoculated with"/>
 <result pre="6 dpc, since the recombinant LSDV-vectored RVF vaccine expresses the" exact="viral" post="GPs, and not the NP. IgM antibody levels rapidly"/>
 <result pre="(ELISA). (A) Mock-vaccinated calves and (B) LSD-RVF.mf-vaccinated calves. Discussion Lumpy" exact="skin disease" post="is no longer an &quot;African�? disease, as it has"/>
 <result pre="(A) Mock-vaccinated calves and (B) LSD-RVF.mf-vaccinated calves. Discussion Lumpy skin" exact="disease" post="is no longer an &quot;African�? disease, as it has"/>
 <result pre="threat of inadvertent or intentional introduction. In contrast, so far" exact="Rift Valley fever" post="has remained within Africa, except for infrequent spread to"/>
 <result pre="and Yemen in the Middle East. It is possible that" exact="Rift Valley fever" post="virus could spread into new regions, including the Americas,"/>
 <result pre="acting together to produce a &quot;perfect storm,�? vaccination against the" exact="disease" post="is not practiced consistently. This results in increasing the"/>
 <result pre="of vaccines, lack of education on their many benefits, and" exact="limited" post="access and available infrastructure to enable their proper storage"/>
 <result pre="vaccines in the medical and veterinary field have offered a" exact="partial" post="solution to these problems. Lumpy skin disease virus has"/>
 <result pre="field have offered a partial solution to these problems. Lumpy" exact="skin disease" post="virus has been investigated for its ability to perform"/>
 <result pre="have offered a partial solution to these problems. Lumpy skin" exact="disease" post="virus has been investigated for its ability to perform"/>
 <result pre="has been investigated for its ability to perform as a" exact="stable" post="and versatile vaccine delivery platform, as has been the"/>
 <result pre="as has been the case for other poxviruses such as" exact="vaccinia" post="virus and canarypox virus, but with the added advantage"/>
 <result pre="second round of recombination after removal of selection pressure (called" exact="transient" post="dominant selection) to remove the markers, resulting in a"/>
 <result pre="is a key element required for the control of virus" exact="infections" post="(33). It was also demonstrated that the PBMCs of"/>
 <result pre="It has been shown that IFN-γ treatment can reduce RVF" exact="infection" post="in rhesus monkeys (34) and in other monkey models"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="der WaalK. Mapping changes in the spatiotemporal distribution of lumpy" exact="skin disease" post="virus. Transbound Emerg Dis. (2019) 66:2045–57. 10.1111/tbed.1325331127984 4.TuppurainenESMAntoniouSETsiamadisETopkaridouMLabusTDebeljakZet al.Field"/>
 <result pre="WaalK. Mapping changes in the spatiotemporal distribution of lumpy skin" exact="disease" post="virus. Transbound Emerg Dis. (2019) 66:2045–57. 10.1111/tbed.1325331127984 4.TuppurainenESMAntoniouSETsiamadisETopkaridouMLabusTDebeljakZet al.Field"/>
 <result pre="experiences gained from the implementation of control measures against lumpy" exact="skin disease" post="in South-East Europe between 2015 and 2017. Prev Vet"/>
 <result pre="gained from the implementation of control measures against lumpy skin" exact="disease" post="in South-East Europe between 2015 and 2017. Prev Vet"/>
 <result pre="of the order Bunyavirales. Arch Virol. (2019) 164:1949–65. 10.1007/s00705-019-04253-631065850 7.DaubneyRHudsonJREnzootic" exact="hepatitis" post="or rift valley fever. J Path and Bact. (1931)"/>
 <result pre="J Path and Bact. (1931) 34:54510.1002/path.1700340418 8.DaviesFG. Risk of a" exact="Rift Valley fever" post="epidemic at the haj in Mecca, Saudi Arabia. Rev"/>
 <result pre="Arabia. Rev Sci Tech. (2006) 25:137–47. 10.20506/rst.25.1.164816796043 9.collab: Centers for" exact="Disease" post="Control and Prevention (CDC)Update: outbreak of rift valley fever—Saudi"/>
 <result pre="Valley Fever. In: Coetzer JAW, Thomson GR, Tustin RC, editors." exact="Infectious" post="Diseases of Livestock with Special Reference to Southern Africa."/>
 <result pre="Fever. In: Coetzer JAW, Thomson GR, Tustin RC, editors. Infectious" exact="Diseases" post="of Livestock with Special Reference to Southern Africa. Volume"/>
 <result pre="al.Genetic analysis of viruses associated with emergence of Rift Valley" exact="Fever" post="virus in Saudi Arabia and Yemen, 2000-1. Emerg Infect"/>
 <result pre="Res. (2013) 98:217–27. 10.1016/j.antiviral.2013.02.01623499648 13.FaburayBWilsonWCGaudreaultNNDavisASShivannaVBawaBet al.. A recombinant Rift Valley" exact="Fever" post="virus glycoprotein subunit vaccine confers full protection against Rift"/>
 <result pre="virus glycoprotein subunit vaccine confers full protection against Rift Valley" exact="Fever" post="challenge in sheep. Sci Rep. (2016) 6:27719. 10.1038/srep2771927296136 14.WallaceDBViljoenGJ."/>
 <result pre="6:27719. 10.1038/srep2771927296136 14.WallaceDBViljoenGJ. Immune responses to recombinants of the South" exact="African" post="vaccine strain of lumpy skin disease virus generated by"/>
 <result pre="to recombinants of the South African vaccine strain of lumpy" exact="skin disease" post="virus generated by using thymidine kinase gene insertion. Vaccine."/>
 <result pre="recombinants of the South African vaccine strain of lumpy skin" exact="disease" post="virus generated by using thymidine kinase gene insertion. Vaccine."/>
 <result pre="10.1016/j.vaccine.2004.10.00615811653 15.WallaceDBEllisCEEspachASmithSJGreylingRRViljoenGJProtective immune responses induced by different recombinant vaccines to" exact="Rift Valley fever." post="Vaccine. (2006) 24:7181–9. 10.1016/j.vaccine.2006.06.04116870311 16.SinghJAUpshurRPadayatchiNXDR-TB in South Africa: no"/>
 <result pre="time for denial or complacency. PLoS Med. (2007) 4:e5010.1371/journal.pmed.004005017253901 17.FalknerFGMossB." exact="Transient" post="dominant selection of recombinant vaccinia viruses. J Virol. (1990)"/>
 <result pre="PLoS Med. (2007) 4:e5010.1371/journal.pmed.004005017253901 17.FalknerFGMossB. Transient dominant selection of recombinant" exact="vaccinia" post="viruses. J Virol. (1990) 64:3108–11. 10.1128/JVI.64.6.3108-3111.19902159565 18.ScheiflingerFDornerFFalknerFG. Transient marker"/>
 <result pre="of recombinant vaccinia viruses. J Virol. (1990) 64:3108–11. 10.1128/JVI.64.6.3108-3111.19902159565 18.ScheiflingerFDornerFFalknerFG." exact="Transient" post="marker stabilisation: a general procedure to construct marker-free recombinant"/>
 <result pre="Transient marker stabilisation: a general procedure to construct marker-free recombinant" exact="vaccinia" post="virus. Arch Virol. (1998) 143:467–74. 10.1007/s0070500503039572548 19.MollaWde JongCMGariGFrankenaKEconomic impact"/>
 <result pre="(2017) 147:100–7. 10.1016/j.prevetmed.2017.09.00329254706 20.FreshneyRIChapter 9, Disaggregation of the tissue and" exact="Primary" post="Culture. In Alan R. Liss, Inc., editor. Culture of"/>
 <result pre="York, NY: Alan R. Liss, Inc., (1987). p. 107–126. 21.WeissKELumpy" exact="Skin Disease" post="virus. Virology Monographs. (1968) 3:111–31. 10.1007/978-3-662-39771-8_3 22.KaraPDMatherASPretoriusAChettyTBabiukSWallaceDB. Characterisation of"/>
 <result pre="NY: Alan R. Liss, Inc., (1987). p. 107–126. 21.WeissKELumpy Skin" exact="Disease" post="virus. Virology Monographs. (1968) 3:111–31. 10.1007/978-3-662-39771-8_3 22.KaraPDMatherASPretoriusAChettyTBabiukSWallaceDB. Characterisation of"/>
 <result pre="10.1007/978-3-662-39771-8_3 22.KaraPDMatherASPretoriusAChettyTBabiukSWallaceDB. Characterisation of putative immunomodulatory gene knockouts of lumpy" exact="skin disease" post="virus in cattle towards an improved vaccine. Vaccine. (2018)"/>
 <result pre="22.KaraPDMatherASPretoriusAChettyTBabiukSWallaceDB. Characterisation of putative immunomodulatory gene knockouts of lumpy skin" exact="disease" post="virus in cattle towards an improved vaccine. Vaccine. (2018)"/>
 <result pre="cattle towards an improved vaccine. Vaccine. (2018) 36:4708–15. 10.1016/j.vaccine.2018.06.01729941325 23.BarnardBJH." exact="Rift Valley fever" post="vaccine - antibody and immune response in cattle to"/>
 <result pre="Improved method for the generation and selection of homogeneous lumpy" exact="skin disease" post="virus (SA-Neethling) recombinants. J Virol Methods. (2007) 146:52–60. 10.1016/j.jviromet.2007.06.00417644196"/>
 <result pre="method for the generation and selection of homogeneous lumpy skin" exact="disease" post="virus (SA-Neethling) recombinants. J Virol Methods. (2007) 146:52–60. 10.1016/j.jviromet.2007.06.00417644196"/>
 <result pre="of the vaccine-vector potential of thymidine kinase-disrupted recombinants of lumpy" exact="skin disease" post="virus (South African vaccine). (Philosophiae Doctor thesis), University of"/>
 <result pre="the vaccine-vector potential of thymidine kinase-disrupted recombinants of lumpy skin" exact="disease" post="virus (South African vaccine). (Philosophiae Doctor thesis), University of"/>
 <result pre="of thymidine kinase-disrupted recombinants of lumpy skin disease virus (South" exact="African" post="vaccine). (Philosophiae Doctor thesis), University of Pretoria, Pretoria, Gauteng"/>
 <result pre="Doctor thesis), University of Pretoria, Pretoria, Gauteng (2005). 26.ViljoenGJNelLHCrowtherJR (eds.)." exact="Disease" post="diagnosis using PCR specific procedures for important veterinary pathogens."/>
 <result pre="Lassa virus, Crimean-Congo haemorrhagic fever virus, Rift valley fever virus," exact="Dengue" post="virus, and Yellow Fever Virus by Real-time Reverse transcription-PCR."/>
 <result pre="fever virus, Rift valley fever virus, Dengue virus, and Yellow" exact="Fever" post="Virus by Real-time Reverse transcription-PCR. J Clin Microbiol. (2002)"/>
 <result pre="Clin Microbiol. (2002) 40:2323–30. 10.1128/JCM.40.7.2323-2330.200212089242 28.TuppurainenESVenterEHCoetzerJA. The detection of lumpy" exact="skin disease" post="virus in samples of experimentally infected cattle using different"/>
 <result pre="Microbiol. (2002) 40:2323–30. 10.1128/JCM.40.7.2323-2330.200212089242 28.TuppurainenESVenterEHCoetzerJA. The detection of lumpy skin" exact="disease" post="virus in samples of experimentally infected cattle using different"/>
 <result pre="a recombinant nucleoprotein for identification of domestic ruminants infected with" exact="Rift Valley fever" post="virus. J Virol Methods. (2011) 177:140–6. 10.1016/j.jviromet.2011.07.01121827790 32.van VurenPJPotgieterACPaweskaJTvan"/>
 <result pre="177:140–6. 10.1016/j.jviromet.2011.07.01121827790 32.van VurenPJPotgieterACPaweskaJTvan DijkAAPreparation and evaluation of a recombinant" exact="Rift Valley fever" post="virus N protein for the detection of IgG and"/>
 <result pre="central and effector memory CD4 T-cells in protective immunity following" exact="infection" post="or vaccination. Immunol. (2018) 154:574–81. 10.1111/imm.12929 34.MorrillJCCzarnieckiCWPetersCJ. Recombinant human"/>
 <result pre="vaccination. Immunol. (2018) 154:574–81. 10.1111/imm.12929 34.MorrillJCCzarnieckiCWPetersCJ. Recombinant human interferon-gamma modulates" exact="Rift Valley fever" post="virus infection in the rhesus monkey. J Interferon Res."/>
 <result pre="154:574–81. 10.1111/imm.12929 34.MorrillJCCzarnieckiCWPetersCJ. Recombinant human interferon-gamma modulates Rift Valley fever" exact="virus infection" post="in the rhesus monkey. J Interferon Res. (1991) 11:297–304."/>
 <result pre="10.1111/imm.12929 34.MorrillJCCzarnieckiCWPetersCJ. Recombinant human interferon-gamma modulates Rift Valley fever virus" exact="infection" post="in the rhesus monkey. J Interferon Res. (1991) 11:297–304."/>
 <result pre="Res. (1991) 11:297–304. 10.1089/jir.1991.11.2971774469 35.WonderlichERCarolineALMcMillenCMWaltersAWReedDSBarratt-BoyesSMet al.. Peripheral blood biomarkers of" exact="disease" post="outcome in a monkey model of Rift Valley Fever"/>
 <result pre="of disease outcome in a monkey model of Rift Valley" exact="Fever" post="encephalitis. J Virol. (2018) 92:e01662–e01617. 10.1128/JVI.01662-1729118127 36.LathanRSimon-ChazottesDJouvionGGodonOMalissenMFlamandMet al.. Innate"/>
 <result pre="92:e01662–e01617. 10.1128/JVI.01662-1729118127 36.LathanRSimon-ChazottesDJouvionGGodonOMalissenMFlamandMet al.. Innate Immune Basis for Rift Valley" exact="Fever" post="Susceptibility in Mouse Models. Sci Rep. (2017) 7:7096. 10.1038/s41598-017-07543-828769107"/>
 <result pre="al.. Innate Immune Basis for Rift Valley Fever Susceptibility in" exact="Mouse" post="Models. Sci Rep. (2017) 7:7096. 10.1038/s41598-017-07543-828769107"/>
</results>
